[
  {
    "ts": "2026-01-10T08:12:10+00:00",
    "headline": "Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed",
    "summary": "Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...",
    "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5c6b4c6d-6f6b-3d56-b934-ebbb50f116a6",
      "content": {
        "id": "5c6b4c6d-6f6b-3d56-b934-ebbb50f116a6",
        "contentType": "STORY",
        "title": "Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed",
        "description": "",
        "summary": "Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...",
        "pubDate": "2026-01-10T08:12:10Z",
        "displayTime": "2026-01-10T08:12:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FqD7IP1YjoMtOLiC1foWBQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DnvRJ7zmyZqa8oFdfcLgCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/madrigal-pharmaceuticals-mdgl-down-13-081210592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-10T15:00:00+00:00",
    "headline": "Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer",
    "summary": "NEW YORK, January 10, 2026--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem",
    "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-additional-chemotherapy-150000320.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "157f4bab-c254-3ab3-9401-fd54820fec68",
      "content": {
        "id": "157f4bab-c254-3ab3-9401-fd54820fec68",
        "contentType": "STORY",
        "title": "Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer",
        "description": "",
        "summary": "NEW YORK, January 10, 2026--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem",
        "pubDate": "2026-01-10T15:00:00Z",
        "displayTime": "2026-01-10T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7cd2bd2e17c5be4a8097fc2d1d5ad20a",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OCLyJAwRJN.5L8irgW6zPQ--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7cd2bd2e17c5be4a8097fc2d1d5ad20a.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0OwtKvYOHRQePadOTjCyvQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7cd2bd2e17c5be4a8097fc2d1d5ad20a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-additional-chemotherapy-150000320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-additional-chemotherapy-150000320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]